This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arikan, S.
Right arrow Articles by Hascelik, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arikan, S.
Right arrow Articles by Hascelik, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2640-2643, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2640-2643.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparison of Two Methods and Three End Points in Determination of In Vitro Activity of Micafungin against Aspergillus spp.

Sevtap Arikan,* Pinar Yurdakul, and Gulsen Hascelik

Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey

Received 17 December 2002/ Returned for modification 14 February 2003/ Accepted 5 May 2003

We investigated the in vitro activity of micafungin against clinical Aspergillus isolates (n = 37) (Aspergillusfumigatus [n = 21], Aspergillusflavus [n = 14], and Aspergillus niger [n = 2]) by using NCCLS M38A microdilution and an investigational disk diffusion assay. Microdilution assay results were evaluated by using the end points of a MIC-2 (measured in micrograms per milliliter) and minimum effective concentration (MEC, measured in micrograms per milliliter; the lowest concentration of micafungin that produces short and aberrant hyphal branchings microscopically). Disk diffusion results were interpreted by measuring the zone(s) of inhibition (ZOI, measured in millimeters). Micafungin proved to be similarly active against all Aspergillus species tested. At 24 h, MIC-2s and MECs were identical. At 48 h, however, MIC-2s increased unpredictably, leading to the loss of a consistent correlation between the two end points. MECs and ZOI remained consistent and correlated at both reading times, suggesting their use as relevant end points in susceptibility testing of micafungin against Aspergillus. All Aspergillus isolates yielded intrazonal growth on disk diffusion agar plates. The intrazonal colonies contained short, aberrant hyphal branchings microscopically. The in vivo significance of these findings remains to be further investigated.


* Corresponding author. Mailing address: Hacettepe University Faculty of Medicine, Department of Microbiology and Clinical Microbiology, 06100 Ankara, Turkey. Phone: 90 312 3051562. Fax: 90 312 3115250. E-mail: sarikan{at}metu.edu.tr.


Antimicrobial Agents and Chemotherapy, August 2003, p. 2640-2643, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2640-2643.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Monzon, A., Buitrago, M. J., Rodriguez-Tudela, J. L. (2009). Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds. Antimicrob. Agents Chemother. 53: 2192-2195 [Abstract] [Full Text]  
  • Plummer, R., Bodkin, J., Power, D., Pantarat, N., Bubb, W. A., Kuchel, P. W., Sorrell, T. C. (2007). Effect of Caspofungin on Metabolite Profiles of Aspergillus Species Determined by Nuclear Magnetic Resonance Spectroscopy. Antimicrob. Agents Chemother. 51: 4077-4084 [Abstract] [Full Text]  
  • Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., Cannon, R. D. (2006). Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 1148-1155 [Abstract] [Full Text]  
  • Carver, P. L (2004). Micafungin. The Annals of Pharmacotherapy 38: 1707-1721 [Abstract] [Full Text]